Eventide Asset Management LLC Buys 502,909 Shares of Celldex Therapeutics, Inc. $CLDX

Eventide Asset Management LLC boosted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 37.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,859,095 shares of the biopharmaceutical company’s stock after buying an additional 502,909 shares during the quarter. Eventide Asset Management LLC’s holdings in Celldex Therapeutics were worth $48,096,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Handelsbanken Fonder AB boosted its holdings in Celldex Therapeutics by 2.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock worth $440,000 after acquiring an additional 500 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the last quarter. DNB Asset Management AS lifted its position in shares of Celldex Therapeutics by 7.7% during the third quarter. DNB Asset Management AS now owns 13,251 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 951 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Celldex Therapeutics during the third quarter valued at about $26,000.

Analyst Ratings Changes

Several research firms recently weighed in on CLDX. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. The Goldman Sachs Group increased their price objective on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Stifel Nicolaus reissued a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Finally, Barclays boosted their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $29.51 on Friday. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -7.59 and a beta of 1.17. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $31.99. The business’s fifty day moving average is $26.34 and its 200-day moving average is $25.98.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. Research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.